Alnylam Pharmaceuticals Inc (ALNY)

Add to Watchlists
Create an Alert
72.60 -1.64  -2.21% NASDAQ Jul 17, 14:48 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
08/02/2019 08:30 EDT Misc Alnylam Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019
08/02/2019 Earnings Alnylam Pharmaceuticals Inc Second Quarter Earnings in 2019 Release
05/01/2019 20:30 EDT Misc Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019
05/01/2019 Earnings Alnylam Pharmaceuticals Inc First Quarter Earnings in 2019 Release
04/25/2019 12:00 EDT Misc Alnylam Pharmaceuticals Inc Annual General Meeting in 2018
02/14/2019 Misc Alnylam Pharmaceuticals Inc Annual Report in 2018
02/07/2019 16:30 EST Misc Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Conference Call in 2018
02/07/2019 Earnings Alnylam Pharmaceuticals Inc Fourth Quarter Earnings in 2018 Release
11/07/2018 Earnings Alnylam Pharmaceuticals Inc Third Quarter Earnings in 2018 Release
11/07/2018 08:30 EST Misc Alnylam Pharmaceuticals Inc Third Quarter Earnings Conference Call in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.alnylam.com
  • Investor Relations URL: http://investors.alnylam.com/index.cfm
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Aug. 02, 2019
  • Last Earnings Release: May. 01, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis, Alnylam has partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Top Fund Holders

Symbol Name Weighting
FBT First Trust NYSE Arca Biotech ETF 3.01%
BBH VanEck Vectors Biotech ETF 2.14%
VGHCX Vanguard Health Care Inv 1.96%
FIJYX Fidelity Advisor® Biotechnology Z 1.72%
FOUSA06SV3 Thrivent Partner Healthcare 1.69%
FBIOX Fidelity® Select Biotechnology 1.52%
XBI SPDR® S&P Biotech ETF 1.40%
LABU Direxion Daily S&P Biotech Bull 3X ETF 1.08%
IBB iShares Nasdaq Biotechnology ETF 1.06%
FCGSX Fidelity® Series Growth Company 0.89%
FGCKX Fidelity® Growth Company K 0.87%
HQH Tekla Healthcare Investors 0.86%

Comparables

Edit

Excel Add-In Codes

  • Name: =YCI("ALNY","name")
  • Description: =YCI("ALNY","description")
  • Sector: =YCI("ALNY","sector")
  • Industry: =YCI("ALNY","industry")
  • Est. Current Fiscal Year End: =YCI("ALNY","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.